Comparative Pharmacology
Head-to-head clinical analysis: COXANTO versus IBUPROFEN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COXANTO versus IBUPROFEN SODIUM.
COXANTO vs IBUPROFEN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of soluble epoxide hydrolase (sEH), increasing levels of epoxyeicosatrienoic acids (EETs), which have vasodilatory, anti-inflammatory, and antifibrotic effects.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
1 g intravenous every 6 hours.
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours (prolonged to 24-30 hours in moderate-to-severe renal impairment, requiring dose adjustment)
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Category C
Category D/X
NSAID
NSAID